These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Lim SC; Lee MS Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049 [TBL] [Abstract][Full Text] [Related]
23. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198 [TBL] [Abstract][Full Text] [Related]
24. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Hui R; Cornish AL; McClelland RA; Robertson JF; Blamey RW; Musgrove EA; Nicholson RI; Sutherland RL Clin Cancer Res; 1996 Jun; 2(6):923-8. PubMed ID: 9816251 [TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. Balasenthil S; Barnes CJ; Rayala SK; Kumar R FEBS Lett; 2004 Jun; 567(2-3):243-7. PubMed ID: 15178330 [TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. Gillett CE; Lee AH; Millis RR; Barnes DM J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905 [TBL] [Abstract][Full Text] [Related]
27. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. van Diest PJ; Michalides RJ; Jannink L; van der Valk P; Peterse HL; de Jong JS; Meijer CJ; Baak JP Am J Pathol; 1997 Feb; 150(2):705-11. PubMed ID: 9033283 [TBL] [Abstract][Full Text] [Related]
28. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma. Lim SC Oncol Rep; 2003; 10(5):1241-9. PubMed ID: 12883688 [TBL] [Abstract][Full Text] [Related]
29. Molecular markers for predicting prostate cancer stage and survival. Dunsmuir WD; Gillett CE; Meyer LC; Young MP; Corbishley C; Eeles RA; Kirby RS BJU Int; 2000 Nov; 86(7):869-78. PubMed ID: 11069416 [TBL] [Abstract][Full Text] [Related]
30. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY. Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396 [TBL] [Abstract][Full Text] [Related]
31. [Expression and Significance of BP1 Gene and Cyclin D1 Gene in Breast Cancer]. Song YC; Fu SD; Wen XP; Ma ZH; Dang CX Ai Zheng; 2007 Jul; 26(7):709-14. PubMed ID: 17626745 [TBL] [Abstract][Full Text] [Related]
32. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979 [TBL] [Abstract][Full Text] [Related]
33. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Cho EY; Choi YL; Han JJ; Kim KM; Oh YL Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636 [TBL] [Abstract][Full Text] [Related]
34. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935 [TBL] [Abstract][Full Text] [Related]
35. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer. Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758 [TBL] [Abstract][Full Text] [Related]
36. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443 [TBL] [Abstract][Full Text] [Related]
37. [Significance and expression of p53, p21(Cip1/WAF1) and Gadd45α in breast neoplasm tissues]. Gao QZ; Fei BJ; Qi XW; Pu Y; Feng YZ Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(34):2389-93. PubMed ID: 23158659 [TBL] [Abstract][Full Text] [Related]
38. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285 [TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
40. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Hui R; Macmillan RD; Kenny FS; Musgrove EA; Blamey RW; Nicholson RI; Robertson JF; Sutherland RL Clin Cancer Res; 2000 Jul; 6(7):2777-87. PubMed ID: 10914724 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]